Topic: antibody-drug conjugates

AbbVie

12. Rova-T

AbbVie’s second entry on this list is Rova-T, an antibody-drug conjugate that finally outstayed its welcome after flunking a phase 3 study in small-cell lung cancer, a difficult-to-treat cancer linked to smoking.
AbbVie

1. Depatux-M

High-grade gliomas are one of the toughest tumors to treat, and the first entrant on our alphabetical list—AbbVie’s antibody-drug conjugate Depatux-M—is one of at least three drugs that failed to hit the mark in this highly aggressive form of brain cancer in 2019.